-
×
Tirzepatide 10mg
1 × $95.00 -
×
Retatrutide 6mg
1 × $95.00
Subtotal: $190.00
Reta/Cagri Blend – 12.5mg/2.5mg
$135.00
Reta/Cagri Blend – 12.5mg/2.5mg is a combination therapeutic agent designed for weight management and metabolic improvement. This blend combines Retatrutide, which regulates appetite and enhances energy expenditure, with Cagri, known for its role in metabolic processes.
Benefits:
- Effective Weight Loss: The synergistic action of both components aids in achieving substantial weight loss.
- Improved Metabolic Function: Enhances overall metabolic health, supporting better energy utilization.
- Convenient Administration: Administered via subcutaneous injection, making it easy for self-administration.
This formulation offers a comprehensive approach for individuals seeking effective obesity management solutions.
Description
Reta/Cagri Blend – 12.5mg/2.5mg is an innovative combination therapeutic agent specifically designed for weight management and metabolic enhancement. This formulation merges two active components: Retatrutide and Cagri, each with distinct mechanisms that work synergistically to promote effective weight loss and improve overall metabolic health.
Mechanism of Action
The Reta/Cagri Blend utilizes a dual approach:
- Retatrutide: This component acts as a dual agonist, mimicking natural hormones that regulate appetite and energy expenditure. By activating specific receptors in the body, Retatrutide suppresses hunger, leading to reduced caloric intake and increased fat burning.
- Cagri: Known for its metabolic-enhancing properties, Cagri further supports the body’s ability to efficiently utilize energy. It plays a role in boosting metabolic processes, ensuring that the body optimally burns calories and fat.
Clinical Benefits
- Effective Weight Loss: The combination of Retatrutide and Cagri
- has been shown to facilitate substantial weight loss, making it a powerful option for individuals struggling with obesity.
- Improved Metabolic Function: By enhancing both appetite regulation and energy utilization, the blend promotes better metabolic health, which is crucial for overall well-being.
- Balanced Hormonal Response: The dual agonist nature of Retatrutide combined with Cagri helps create a balanced hormonal environment, supporting long-term weight management.
- Convenient Administration: The blend is administered via subcutaneous injection, making it simple for patients to self-administer and integrate into their daily routines.
Treatment Considerations
Before beginning treatment with Reta/Cagri Blend, it is essential for patients to consult with healthcare providers to determine its suitability for their specific health conditions. While this combination therapy can be effective for weight management, it should be used in conjunction with a balanced diet and regular physical activity for optimal results.
Conclusion
Reta/Cagri Blend – 12.5mg/2.5mg represents a significant advancement in the pharmacological approach to obesity and metabolic disorders. By leveraging the synergistic effects of its components, this blend offers a comprehensive strategy for weight loss and metabolic improvement, providing a promising solution for individuals seeking to achieve and maintain a healthier weight and enhance their overall health and well-being.
Related products
-
CJC-1295 No DAC 5mg
High-purity CJC-1295 No DAC peptide for research use only. 5mg per vial. Not for human or animal consumption. CJC-1295 No DAC 5mg is offered as a research-use-only peptide, supplied in lyophilized form for laboratory analysis and experimentation. This compound is typically explored in controlled research environments focused on understanding peptide-chain behavior, protein synthesis, and signal transduction mechanisms. Each vial contains 5mg of high-purity material and is not intended for human or animal use.- Form: Lyophilized powder
- Contents: 5mg per vial
- Purity: ≥99%
- Storage: Store at -20°C for long-term stability
-
Tirzepatide 10mg
Tirzepatide 10 mg is a ≥ 99 % pure dual-receptor peptide supplied as a lyophilized powder for in-vitro GLP-1 / GIP research. For laboratory use only—no human or veterinary applications. Tirzepatide is a synthetic peptide under investigation for concurrent agonist activity at GLP-1 and GIP receptors. Ongoing in-vitro studies explore dual-receptor signalling pathways relevant to metabolic research models.Specification
- Peptide Name: Tirzepatide
- Content: 10 mg lyophilized powder (requires reconstitution)
- Purity: ≥ 99 % (HPLC / MS certificate available)
- Manufacturing: ISO 9001:2015 & cGMP-audited facility
- Intended Use: In-vitro laboratory research only
Storage & Handling
- Prior to reconstitution: store ≤ 8 °C in a dry environment
- After reconstitution: refrigerate 2 – 8 °C and use within 30 days
- For extended preservation: aliquot and freeze at −20 °C
- Avoid repeated freeze–thaw cycles
Compliance Notice
Supplied exclusively to qualified professionals for controlled laboratory applications. No dosage or administration guidance is provided. Buyer assumes responsibility for safe handling and regulatory adherence. $95.00 -
Tirzepatide 15mg
Tirzepatide 15 mg is a ≥ 99 % pure dual-receptor peptide supplied as a lyophilized powder for in-vitro GLP-1 / GIP research. For laboratory use only—no human or veterinary applications. Tirzepatide is a synthetic peptide under investigation for concurrent agonist activity at GLP-1 and GIP receptors. Current in-vitro studies explore dual-receptor signalling pathways relevant to metabolic research models.Specification
- Peptide Name: Tirzepatide
- Content: 15 mg lyophilized powder (requires reconstitution)
- Purity: ≥ 99 % (HPLC / MS certificate available)
- Manufacturing: ISO 9001:2015 & cGMP-audited facility
- Intended Use: In-vitro laboratory research only
Storage & Handling
- Prior to reconstitution: store ≤ 8 °C in a dry environment
- After reconstitution: refrigerate 2 – 8 °C and use within 30 days
- For extended preservation: aliquot and freeze at −20 °C
- Avoid repeated freeze–thaw cycles
Compliance Notice
Supplied exclusively to qualified professionals for controlled laboratory applications. No dosage or administration guidance is provided. Buyer assumes responsibility for safe handling and regulatory adherence. $140.00 -
Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin Blend (12mg)
Further, preliminary research involving CJC-1295 (Mod GRF 1-29) 1-29 indicates a potential rise in nocturnal growth hormone levels, as well as serum levels of IGF-I and IGFBP-3, and GHBP concentrations.(10) Consequently, male research models exposed to the peptide over a span of four months seemingly gained an average of 1.26 kg in lean body mass. Additionally, research suggests that the peptide might influence an increase in skin thickness among males and may possibly enhance insulin sensitivity. $140.00
Reviews
There are no reviews yet.